p27Kip1 is overexpressed in very early stages of hepatocarcinogenesis

Cancer Science

Volumn 99, Issue 11, 2008, Pages 2152-2159

  Yachida, Shinichi ^a   Sakamoto, Michiie ^b   Imaida, Katsumi ^c   Yokohira, Masanao ^c   Saoo, Kousuke ^c   Okano, Keiichi ^a   Wakabayashi, Hisao ^a   Maeta, Hajime ^a   Suzuki, Yasuyuki ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KAGAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; S PHASE KINASE ASSOCIATED PROTEIN 2;

ADENOMA; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; EARLY CANCER; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RNA, MESSENGER; S-PHASE KINASE-ASSOCIATED PROTEINS;

EID: 55449109546     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00923.x     Document Type: Article

References (42)

1. Sakamoto M, Hirohashi S, Shimosato Y. Early stages of multistep hepatocarcinogenesis: Adenomatous hyperplasia and early hepatocellular carcinoma. Human Pathol 1991; 22: 172-8.
2. Sakamoto M, Hirohashi S. Natural history and prognosis of adenomatous hyperplasia and early hepatocellular carcinoma. Multi-institutional analysis of 53 nodules followed up for more than 6 months and 141 patients with single early hepatocellular carcinoma treated by surgical resection or percutaneous ethanol injection. Jpn J Clin Oncol 1998; 28: 604-8.
3. Oikawa T, Ojima H, Yamasaki S, Takayama T, Hirohashi S, Sakamoto M. Multistep and multicentric development of hepatocellular carcinoma: histological analysis of 980 resected nodules. J Hepatol 2005; 42: 225-9.
4. Takayama T, Makuuchi M, Hirohashi S et al. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 1990; 336: 1150-3.
5. Morimitsu Y, Hsia CC, Kojiro M, Tabor E. Nodules of less-differentiated tumor within or adjacent to hepaocellular carcinoma. reactive expression of transforming growth factor-alpha and its receptor in the different areas of tumor. Human Pathol 1995; 26: 1126-32.
6. Kip1 is haplo-insufficient for tumor suppression. Nature 1998; 396: 177-80.
7. Lee MH, Reynisdottir I, Massague J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995; 9: 639-49.
8. Polyak K, Lee MH, Erdjument-Bromage H et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78: 59-66.
9. Kip1 and poor prognosis in oral squamous cell carcinomas. Oncology 2003; 65: 355-62.
10. Ito Y, Matsuura N, Sakon M et al. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology 1999; 30: 90-9.
11. Tannapfel A, Grund D, Katalinic A et al. Decreased expression of p27 protein is associated with advanced tumor stage in hepatocellular carcinoma. Int J Cancer 2000; 89: 350-5.
12. Carrano AC, Eytan E, Hershko A, Pagano M. Skp2 is required for ubiquitin-mediated degradation of Cdk inhibitor p27. Nat Cell Biol 1999; 1: 193-7.
13. Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1999; 1: 207-14.
14. Masuda T, Inoue H, Sonoda H et al. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: Modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res 2002; 62: 3819-25.
15. Kip1 and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 2001; 91: 1745-51.
16. Sonoda H, Inoue H, Ogawa K, Utsunomiya T, Masuda T, Mori M. Significance of Skp2 expression in primary breast cancer. Clin Cancer Res 2006; 12: 1215-20.
17. Hirohashi S, Ishak KG, Kojiro M et al. Hepatocellular carcinoma. In: Hamilton SR, Aaltonen LA, eds. Pathology and Genetics of Tumors of the Digestive System. Lyon: IARC Press, 2000; 159-72.
18. Liver Cancer Study Group of Japan. General Rules for the Clinical and Pathological Study of Primary Liver Cancer. Tokyo: Kanehara, 2003.
19. Goto A, Niki T, Moriyama S et al. Immunohistochemical study of Skp2 and Jab1, two key molecules in the degradation of P27, in lung adenocarcinoma. Pathol Int 2004; 54: 675-81.
20. Seki R, Okamura T, Koga H et al. Prognostic significance of the F-box protein Skp2 expression in diffuse large B-cell lymphoma. Am J Hematol 2003; 73: 230-5.
21. Yeh TS, Chen TC, Chen MF. Dedifferentiation of human hepatocellular carcinoma up-regulates telomerase and Ki-67 expression. Arch Surg 2000; 135: 1334-9.
22. Fiorentino M, Altimari A, D'Errico A et al. Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin Cancer Res 2000; 6: 3966-72.
23. Kip1 is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma. J Hepatol 2003; 38: 591-7.
24. Chuma M, Sakamoto M, Yamazaki K et al. Expression profiling in multistage hepatocarcinogenesis: Identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 2003; 37: 198-207.
25. Shibata R, Du Mori T, W et al. Overexpression of cyclase-associated protein 2 in multistage hepatocarcinogenesis. Clin Cancer Res 2006; 12: 5363-8.
26. Sakamoto M. Pathology of early hepatocellular carcinoma. Hepatol Res; 37: S135-8.
27. Kip1 gene in hepatocellular carcinoma. Cancer Lett 2000; 153: 169-73.
28. WAF1/CIP1 in primary hepatocellular carcinoma: Clinicopathologic correlation and survival analysis. Hum Pathol 2001; 32: 778-84.
29. 1 -cyclin-dependent kinase 4 complexes and poor prognosis in hepatocellular carcinoma. Clin Cancer Res 2003; 9: 3389-96.
30. Kip1 expression in hepatocellular carcinomas. Cancer Lett 1998; 132: 67-73.
31. skp2 pathway in murine models of lung and colon cancer. Proc Natl Acad Sci USA 2006; 103: 14009-14.
32. Sanada T, Yokoi S, Arii S, Yasui K, Imoto I, Inazawa J. Skp2 overexpression is a p27Kip1-independent predictor of poor prognosis in patients with biliary tract cancers. Cancer Sci 2004; 95: 969-76.
33. Li SH, Li CF, Sung MT et al. Skp2 is an independent prognosticator of gallbladder carcinoma among p27 (Kip1)-interacting cell cycle regulators: An immunohistochemical study of 62 cases by tissue microarray. Mod Pathol 2007; 20: 497-507.
34. Yokoi S, Yasui K, Iizawa T, Takahashi T, Fujisawa T, Inazawa J. Down-regulation of SKP2 induces apoptosis in lung-cancer cells. Cancer Sci 2003; 94: 344-9.
35. Gstaiger M, Jordan R, Lim M et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA 2001; 98: 5043-8.
36. Nakayama K, Nagahama H, Minamishima YA et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27 (Kip1), polyploidy and centrosome overduplication. EMBO J 2000; 19: 2069-81.
37. Chiappetta G, De Marco C, Quintiero A et al. Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer. Endocr Relat Cancer 2007; 14: 405-20.
38. Signoretti S, Di Marcotullio L, Richardson A et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 2002; 110: 633-41.
39. Drobnjak M, Melamed J, Taneja S et al. Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients. Clin Cancer Res 2003; 9: 2613-9.
40. Radke S, Pirkmaier A, Germain D. Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer. Oncogene 2005; 24: 3448-58.
41. 1 transition mediated by a Skp2-independent ubiquitination pathway. J Biol Chem 2001; 276: 48937-43.
42. 1 phase. J Biol Chem 2005; 280: 17694-700.